Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: opioid

U.S. Senate Committee Advances Azar Nomination as Health Secretary

Reuters Staff  |  January 18, 2018

WASHINGTON (Reuters)—A U.S. Senate committee on Wednesday voted to move forward the nomination of Alex Azar, a former drug industry executive and lobbyist whom President Donald Trump has tapped to be the next secretary of Health and Human Services. The Senate Finance Committee voted 15-12 to advance Azar’s nomination, with all but one Democrat opposing….

Filed under:Legislation & Advocacy Tagged with:nomination of Alex Azarsecretary of Health and Human ServicesU.S. Senate Finance Committee

Health Secretary Nominee Indicates Support for Medicaid Overhaul

Yasmeen Abutaleb  |  January 9, 2018

WASHINGTON (Reuters)—Alex Azar, a former drug industry executive and lobbyist nominated to run the U.S. Department of Health and Human Services, indicated on Tuesday he supported a Republican bid to overhaul Medicaid and again vowed to tackle high drug prices. Azar appeared before the Senate Finance Committee on Tuesday, which will ultimately decide whether to…

Filed under:Legislation & AdvocacyProfessional Topics Tagged with:Alex AzarDepartment of Health and Human ServicesTrump administrationU.S. Department of Health and Human Services

Unwise Choices: EHRs, PBMs, Drug Costs Are Leading to Physician Burnout

Simon M. Helfgott, MD  |  November 5, 2017

My dear electronic health records How do I dislike thee? Let me count the ways Adaptation of Sonnet 43 By Elizabeth Barrett Browning, 1806–1861 As my tenure as physician editor winds down, it’s worth reviewing some of the more nettlesome issues confronting clinicians that have been previously discussed in these pages and gauge their current…

Filed under:EMRsInsuranceOpinionPractice SupportRheuminationsSpeak Out RheumWorkforce Tagged with:burnoutCareercostsdrugEHRElectronic health recordsHealthcareinsurancepharmacy benefit managersphysicianPractice Managementrheumatologist

Pain Treatments Move Closer to U.S. Market

Michele B. Kaufman, PharmD, BCGP  |  October 18, 2017

Two pain treatments, extended-release injectable suspension triamcinolone acetonide (Zilretta) and meloxicam, have seen movement at the U.S. Food and Drug Administration (FDA). In October, the agency approved Zilretta to treat osteoarthritis (OA) knee pain and accepted a new drug application for meloxicam to treat pain. FDA Approves Zilretta On Oct. 6, the FDA approved extended-release,…

Filed under:AnalgesicsDrug Updates Tagged with:Knee Osteoarthritis (OA)knee painmeloxicamosteoarthritis (OA)PainPain Medicationpost-surgeryZilretta

Flexion’s Knee Pain Drug Gets FDA Approval

Divya Grover  |  October 9, 2017

(Reuters)—Flexion Therapeutics Inc. said its injectable drug to treat osteoarthritis-related knee pain was approved by the U.S. Food and Drug Administration. The approval comes at a time when U.S. federal authorities are implementing a slew of measures to combat opioid abuse, with President Donald Trump in August declaring the opioid epidemic a national emergency. The…

Filed under:ConditionsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:FDAFood and Drug Administrationknee painosteoarthritis (OA)triamcinolone acetonideU.S. Food and Drug AdministrationZilretta

Cigna to End OxyContin Painkiller Coverage, Signs Contract for Alternative

Deena Beasley  |  October 5, 2017

(Reuters)—Amid a growing U.S. opioid addiction, health insurer Cigna Corp will stop covering OxyContin, the opioid painkiller sold by Purdue Pharma LP, as of January 1 and will instead cover an equivalent with a formulation less vulnerable to abuse, the company said on Wednesday. The insurer has signed a “value-based contract” with Collegium Pharmaceutical Inc…

Filed under:Drug Updates Tagged with:Cigna Corp.Collegium Pharmaceutical Incopioid crisisOxyContinpainkiller coveragePurdue Pharma LPU.S. opioid addictionXtampza ER

Washington State Sues OxyContin Maker Purdue Pharma

Nate Raymond  |  September 29, 2017

(Reuters)—Washington state on Thursday sued OxyContin maker Purdue Pharma LP, becoming the latest state or local government to file a lawsuit seeking to hold pharmaceutical companies accountable for a national opioid addiction epidemic. The city of Seattle also filed a separate lawsuit against Purdue as well as units of Teva Pharmaceutical Industries Ltd, Johnson and…

Filed under:Drug UpdatesLegal Updates Tagged with:Allergan Plc.Endo International PlcJohnson and Johnsonnational opioid addiction epidemicopioid crisisOxyContinPurdue Pharma LPTeva Pharmaceutical Industries LtdWashington state lawsuit

Many Drug Companies Fail to Conduct Timely Safety Checks on Medicines after FDA Approval

Gene Emery  |  September 22, 2017

(Reuters Health)—In the rush to approve new medicines, the U.S. Food and Drug Administration often requires drug companies to study possible side effects and alternative doses for medicines once they hit the broader market. A September 20 online analysis in the New England Journal of Medicine concludes that, in many cases, that’s not being done….

Filed under:Drug UpdatesEthics Tagged with:Dartmouth Institute for Health Policy and Clinical PracticeFDA approvalGilenya (fingolimod)Indivior's SuboxoneU.S. Food and Drug Administration

Acupuncture & Electrotherapy May Help Patients after Total Knee Arthroplasty

Lara C. Pullen, PhD  |  September 18, 2017

A new review examined how drug-free interventions affect pain relief and analgesic consumption for patients who have had knee surgery. Although little evidence shows these treatments reduce actual pain, electrotherapy and acupuncture may help patients delay their postoperative use of opioids…

Filed under:ConditionsOsteoarthritis and Bone Disorders Tagged with:Acupunctureelectrotherapyknee painPaintotal knee arthroplasty

S.C. Sues Purdue, Maker of OxyContin, Over Deceptive Marketing

Nate Raymond  |  August 16, 2017

(Reuters)—On Tuesday, South Carolina sued Purdue Pharma LP, becoming the latest state or local government to accuse the OxyContin maker of deceptive marketing practices that have contributed to a national opioid addiction epidemic. The lawsuit by South Carolina Attorney General Alan Wilson, filed in Richland County Court of Common Pleas in Columbia, accuses the company…

Filed under:Drug UpdatesLegal Updates Tagged with:AddictionLegalOpioid abuseopioid crisisopioid drug probeopioid epidemicOpioids

  • « Previous Page
  • 1
  • …
  • 17
  • 18
  • 19
  • 20
  • 21
  • …
  • 32
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences